Clinical efficacy of Huangqi Guizhi Wuwu decoction in treating peripheral neuropathy of multiple myeloma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072765

Enrollment

Unknown

Registered

2023-06-25

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peripheral neuropathy of multiple myeloma

Interventions

Traditional Chinese Medicine Group:Oral administration of Huangqi Guizhi Wuwu Tang, Zhijing San, and Mecobalamin tablets

control group:Oral methylcobalamin tablets

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meets diagnostic criteria 2. Age 18-80 years old 3. The patient has multiple myeloma and peripheral neuropathy for less than 1 year 4. Voluntary signing of informed consent form

Exclusion criteria

Exclusion criteria: 1. Does not meet the inclusion criteria 2. Individuals who are allergic to the drugs in this study 3. Neuropathy caused by other diseases or drugs (such as diabetes peripheral neuropathy) 4. Patients with severe cardiovascular and cerebrovascular diseases, liver and kidney dysfunction, mental illness, or other malignant tumors. 5. Currently undergoing other clinical trial studies. 6. Pregnant or lactating women;

Design outcomes

Primary

Measure	Time frame
nerve conduction velocity;Pain Digital Evaluation Scale;Classification of peripheral neuropathy;FACT/GOG-Ntx Neurotoxicity Assessment Tool Scale;Extracellular signal-regulated kinase 2;	—

Countries

CHINESE

Contacts

Public ContactShi Zhexin

The First Teaching Hospital of Tianjin University of TCM

shzhx0604@163.com+86 137 5268 9966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026